CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

Core Insights - CERo Therapeutics has initiated dosing for the third patient in the starting dose cohort of its Phase 1 clinical trial for CER-1236 targeting acute myeloid leukemia (AML) [1][2] - The trial aims to evaluate the safety, tolerability, and preliminary activity of CER-1236 in various AML patient populations, including those with relapsed/refractory disease and newly diagnosed cases with TP53 mutations [2][4] - The company has observed pharmacokinetic data indicating cell expansion at the lowest dose level and has modified the protocol to allow for a second infusion in the same subject to gather more data [3] Company Overview - CERo Therapeutics is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that integrates characteristics of both innate and adaptive immunity [4] - The company's novel cellular immunotherapy platform aims to redirect patient-derived T cells to eliminate tumors through mechanisms that enhance the therapeutic potential beyond current CAR-T therapies [4]